OROS-Methylphenidate

DRUG5 trials

Sponsors

Massachusetts General Hospital, Johnson & Johnson Taiwan Ltd, Children's Hospital of Philadelphia

Conditions

Attention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity Disorder (ADHD)Executive Function Deficits (EFD)Healthy

Phase 2

L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults

CompletedNCT01853280

Massachusetts General HospitalAttention Deficit Hyperactivity Disorder

Start: 2014-05-31End: 2017-09-30Updated: 2017-11-14

Phase 4

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

CompletedNCT00302458

Massachusetts General HospitalHealthy

Start: 2006-01-31End: 2007-06-30Updated: 2016-02-29

A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder

CompletedNCT00518232

Johnson & Johnson Taiwan LtdAttention Deficit Hyperactivity Disorder

Start: 2006-09-30End: 2007-06-30Updated: 2010-04-28

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

CompletedNCT00530257

Children's Hospital of PhiladelphiaAttention Deficit Hyperactivity Disorder

Start: 2004-06-30End: 2008-06-30Updated: 2011-12-19

Unknown Phase

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

CompletedNCT01533493

Massachusetts General HospitalAttention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)

Start: 2012-05-31End: 2013-08-31Updated: 2014-04-08